KLRK1 and neoplasm: Similarly, in NK cells, efforts have been directed towards developing bispecific or trispecific NK cell engagers (TriKE) targeting NKG2D, NKp46, NKp30 with or without CD16 targeting, and tumor antigens like CD30 and CD33 [325].